À retenir
Through a modified Delphi process, experts confirmed 17 consensus statements on sarcopenia prevention, assessment and management, including adopting the EWGSOP2 definition; agreement was strongest for healthy lifestyle (100%) and tailored resistance training (92.5%). These are opinion-based recommendations from a small expert panel, not trial results.
Study design
Revue des preuves
Reading basis
Published abstract
Reading focus
Design & applicability
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Sarcopenia is age-related loss of muscle mass, strength and physical performance, yet there is no international agreed definition and no current Australian and New Zealand guidance. The authors, a task force of the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR), set out to build consensus guidelines for prevention, assessment, management and research.
Population et méthode
A four-phase modified Delphi process between July 2020 and August 2021, informed by consumers. Phase 1 was a structured meeting of 29 Task Force members and a systematic literature search. In Phase 2, topic experts rated 18 statements on 11-point Likert scales (agreement threshold >80%) and answered five multiple-choice questions; statements with moderate agreement (70%-80%) were revised and statements below 70% rejected. Phase 3 covered six revised statements and three additional questions, incorporating a parallel Consumer Expert Delphi study. Phase 4 finalized the statements.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Topic experts took part in Phase 2 (Australia n = 62, 92.5%; New Zealand n = 5, 7.5%; mean age 45.7 years, SD 11.8; 56.7% women, 56.7% health professionals, 40.3% researchers). 15 of 18 statements (83.3%) were accepted with strong agreement.
- 2Agreement was strongest for encouraging a healthy lifestyle (100%) and offering tailored resistance training to people with sarcopenia (92.5%).
- 3In Phase 3, 47 experts accepted 5 of 6 revised statements (83.3%), and 87.9% preferred the revised European Working Group for Sarcopenia in Older Persons (EWGSOP2) definition.
- 4The Task Force confirmed 17 statements with agreement above 80%.
Limites et incertitude
- 1The recommendations reflect expert and consumer opinion, not new trial data, and the abstract does not grade the evidence behind each statement.
- 2The expert panel was small and almost entirely Australian (n = 62 in Phase 2, versus n = 5 from New Zealand).
- 3Agreement thresholds are set a priori, so high agreement does not mean the underlying evidence is strong.
- 4This reading is based on the abstract only, which does not list the 17 statements.
Mise en perspective
The panel most strongly backed a healthy lifestyle and tailored resistance training for people with sarcopenia. These are consensus recommendations for professionals, not a diagnosis tool. Concerns about muscle loss and decisions about a training program should be raised with your clinician.
Vos données
Grip strength, gait speed and muscle mass are clinical measures; a wearable can support the lifestyle side by logging steps, activity and strength sessions. Compare those logs with the same device over months, and rely on a clinician for any sarcopenia assessment.
Comprendre ce type de preuve
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Background
Sarcopenia is an age-associated skeletal muscle condition characterized by low muscle mass, strength, and physical performance. There is no international consensus on a sarcopenia definition and no contemporaneous clinical and research guidelines specific to Australia and New Zealand. The Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Sarcopenia Diagnosis and Management Task Force aimed to develop consensus guidelines for sarcopenia prevention, assessment, management and research, informed by evidence, consumer opinion, and expert consensus, for use by health professionals and researchers in Australia and New Zealand.
Methods
A four-phase modified Delphi process involving topic experts and informed by consumers, was undertaken between July 2020 and August 2021. Phase 1 involved a structured meeting of 29 Task Force members and a systematic literature search from which the Phase 2 online survey was developed (Qualtrics). Topic experts responded to 18 statements, using 11-point Likert scales with agreement threshold set a priori at >80%, and five multiple-choice questions. Statements with moderate agreement (70%-80%) were revised and re-introduced in Phase 3, and statements with low agreement (<70%) were rejected. In Phase 3, topic experts responded to six revised statements and three additional questions, incorporating results from a parallel Consumer Expert Delphi study. Phase 4 involved finalization of consensus statements.
Results
Topic experts from Australia (n = 62, 92.5%) and New Zealand (n = 5, 7.5%) with a mean ± SD age of 45.7 ± 11.8 years participated in Phase 2; 38 (56.7%) were women, 38 (56.7%) were health professionals and 27 (40.3%) were researchers/academics. In Phase 2, 15 of 18 (83.3%) statements on sarcopenia prevention, screening, assessment, management and future research were accepted with strong agreement. The strongest agreement related to encouraging a healthy lifestyle (100%) and offering tailored resistance training to people with sarcopenia (92.5%). Forty-seven experts participated in Phase 3; 5/6 (83.3%) revised statements on prevention, assessment and management were accepted with strong agreement. A majority of experts (87.9%) preferred the revised European Working Group for Sarcopenia in Older Persons (EWGSOP2) definition. Seventeen statements with strong agreement (>80%) were confirmed by the Task Force in Phase 4.
Conclusions
The ANZSSFR Task Force present 17 sarcopenia management and research recommendations for use by health professionals and researchers which includes the recommendation to adopt the EWGSOP2 sarcopenia definition in Australia and New Zealand. This rigorous Delphi process that combined evidence, consumer expert opinion and topic expert consensus can inform similar initiatives in countries/regions lacking consensus on sarcopenia.
Sources et attribution
Consensus guidelines for sarcopenia prevention, diagnosis and management in Australia and New Zealand.
Zanker J, Sim M, Anderson K, Balogun S, Brennan-Olsen SL, Dent E, Duque G, Girgis CM, Grossmann M, Hayes A, Henwood T, Hirani V, Inderjeeth C, Iuliano S, Keogh J, Lewis JR, Lynch GS, Pasco JA, Phu S, Reijnierse EM, Russell N, Vlietstra L, Visvanathan R, Walker T, Waters DL, Yu S, Maier AB, Daly RM, Scott D.
Journal of cachexia, sarcopenia and muscle · 2022-11-09
DOI: 10.1002/jcsm.13115 ↗PubMed · 36349684 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

